诺和诺德口服版司美格鲁肽处方量突破2.6万张

Core Insights - Novo Nordisk's oral semaglutide (Wegovy) has shown strong initial prescription numbers in the U.S. market, with over 26,000 prescriptions in its second full trading week [1][2] - The competitive landscape in the weight loss drug market is intense, and investors are closely monitoring prescription data to assess Novo Nordisk's ability to leverage its first-mover advantage against competitors like Eli Lilly [1] - Barclays analysts highlighted that the prescription volume reached 26,109 by the week ending January 23, indicating a strong debut performance for the oral medication [1] Prescription Data Summary - Wegovy was launched in the U.S. on January 5, with 3,071 prescriptions recorded in the first four days [2] - In the first complete trading week ending January 16, prescriptions exceeded 18,000 [2]